EGR2 and thyroid gland carcinoma: EGR2 inhibition significantly restored miR-17-5p-inhibitor-reduced cell growth, cell migration, and cell invasion in thyroid cancer (Figure 4(a–d)), indicating that miR-17-5p promotes thyroid carcinoma progression by suppressing EGR2.